← Back to Search

Low Sugar Protein Pacing + Intermittent Fasting for Weight Loss

N/A
Waitlist Available
Led By Paul J Arciero, PhD
Research Sponsored by Skidmore College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 weeks, 8 weeks, 1 year and 2 year of the case study
Awards & highlights

Study Summary

This trial will study the effects of protein pacing and intermittent fasting on weight loss, body composition, blood sugar, lipids, and other markers in 40 obese men and women.

Who is the study for?
This trial is for overweight or obese non-smoking men and women who have been weight stable for the past 6 months, with no cardiovascular or metabolic diseases. They should be sedentary or lightly active and not pregnant. People with diabetes, significant heart disease, eating disorders, certain allergies, cancer treatments, or fasting intolerances cannot join.Check my eligibility
What is being tested?
The study tests a diet called protein pacing combined with intermittent fasting (P-IF) over an 8-week period to see its effects on body composition, blood sugar levels, lipids (fats), anti-aging markers, hunger feelings and gut health. Participants will also follow up for an additional year to monitor long-term weight loss maintenance.See study design
What are the potential side effects?
Potential side effects may include discomfort from dietary changes such as hunger during fasting periods; digestive issues due to new foods introduced in the diet; possible nutrient deficiencies if the diet lacks variety; and fatigue due to calorie restriction.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 weeks, 8 weeks, 1 year and 2 year of the case study
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 weeks, 8 weeks, 1 year and 2 year of the case study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in body weight
Secondary outcome measures
Change in blood lipid levels
Change in blood pressure
Change in energy intake
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Protein pacing and intermittent fastingExperimental Treatment1 Intervention
During the 8-week weight loss (WL) phase, participants assigned to the P-IF will consist of P days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to ~1500 and ~1800 calories per day, women and men, respectively during P days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The P-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of P and two days of IF, and the second subgroup will consist of six days of P and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a P diet and 1 day IF.
Group II: Heart HealthyExperimental Treatment1 Intervention
The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming <35% of kcal as fat; 50%-60% of kcal as carbohydrates; <200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HH
2013
N/A
~50

Find a Location

Who is running the clinical trial?

Skidmore CollegeLead Sponsor
18 Previous Clinical Trials
1,012 Total Patients Enrolled
4 Trials studying Weight Loss
96 Patients Enrolled for Weight Loss
Arizona State UniversityOTHER
283 Previous Clinical Trials
109,474 Total Patients Enrolled
2 Trials studying Weight Loss
244 Patients Enrolled for Weight Loss
Isagenix International LLCIndustry Sponsor
5 Previous Clinical Trials
174 Total Patients Enrolled
1 Trials studying Weight Loss
43 Patients Enrolled for Weight Loss

Media Library

HH Clinical Trial Eligibility Overview. Trial Name: NCT04327141 — N/A
Weight Loss Research Study Groups: Protein pacing and intermittent fasting, Heart Healthy
Weight Loss Clinical Trial 2023: HH Highlights & Side Effects. Trial Name: NCT04327141 — N/A
HH 2023 Treatment Timeline for Medical Study. Trial Name: NCT04327141 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is eligibility for this research study restricted to individuals younger than 80 years of age?

"This medical experiment is seeking volunteers with an age between 25 and 65."

Answered by AI

Am I eligible to partake in this medical research experiment?

"This research is looking for 40 participants aged 25-65 who are overweight or obese and have not made any changes to their weight in the last 6 months. Additionally, applicants must be sedentary or lightly active (<30 min, 2d/wk of structured physical activity), non-smokers with no known cardiovascular or metabolic diseases as assessed by a medical history and comprehensive physical examination from their healthcare provider."

Answered by AI

Are participants currently being admitted for this clinical trial?

"According to information available on clinicaltrials.gov, this experiment is no longer recruiting subjects as it was last updated on April 19th 2022. First posted in September 3rd 2020, 234 other studies are presently accepting participants for their trials."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
~9 spots leftby Apr 2025